Baricitinib in Patients with Refractory Rheumatoid Arthritis
Baricitinib in Patients with Refractory Rheumatoid Arthritis
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this phase 3 study involving patients with an inadequate response to biologic disease-modifying antirheumatic drugs, baricitinib, an oral JAK1 and JAK2 inhibitor, led to clinical improvement at 12 weeks. Infections were more frequent with baricitinib than with placebo.
The discomfort, disability, and joint damage that characterize rheumatoid...
Alternative Titles
Full title
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1777982803
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1777982803
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1507247
